Cencora, Inc.
Cencora, Inc. (COR) Stock Competitors & Peer Comparison
See (COR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COR | $266.17 | +1.64% | 51.8B | 20.41 | $13.04 | +0.88% |
| MCK | $761.89 | -1.81% | 91.7B | 19.85 | $38.41 | +0.41% |
| CAH | $200.37 | +0.30% | 46.9B | 30.55 | $6.56 | +1.01% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $72.92 | +0.32% | 8.3B | 22.03 | $3.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $36.28 | +1.28% | 2.3B | 43.25 | $0.84 | N/A |
| PBH | $46.44 | -0.34% | 2.2B | 11.88 | $3.91 | N/A |
| ACH | $2.80 | +2.19% | 214.1M | -2.04 | -$1.37 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
Stock Comparison
COR vs MCK Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, MCK has a market cap of 91.7B. Regarding current trading prices, COR is priced at $266.17, while MCK trades at $761.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas MCK's P/E ratio is 19.85. In terms of profitability, COR's ROE is +1.16%, compared to MCK's ROE of -2.65%. Regarding short-term risk, COR is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check MCK's competition here
COR vs CAH Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, CAH has a market cap of 46.9B. Regarding current trading prices, COR is priced at $266.17, while CAH trades at $200.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas CAH's P/E ratio is 30.55. In terms of profitability, COR's ROE is +1.16%, compared to CAH's ROE of -0.56%. Regarding short-term risk, COR is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CAH's competition here
COR vs ABC Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $266.17, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +1.16%, compared to ABC's ROE of +1.16%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ABC's competition here
COR vs HSIC Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, HSIC has a market cap of 8.3B. Regarding current trading prices, COR is priced at $266.17, while HSIC trades at $72.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas HSIC's P/E ratio is 22.03. In terms of profitability, COR's ROE is +1.16%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check HSIC's competition here
COR vs PDCO Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $266.17, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +1.16%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check PDCO's competition here
COR vs GRDN Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, GRDN has a market cap of 2.3B. Regarding current trading prices, COR is priced at $266.17, while GRDN trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas GRDN's P/E ratio is 43.25. In terms of profitability, COR's ROE is +1.16%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, COR is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check GRDN's competition here
COR vs PBH Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, COR is priced at $266.17, while PBH trades at $46.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas PBH's P/E ratio is 11.88. In terms of profitability, COR's ROE is +1.16%, compared to PBH's ROE of +0.10%. Regarding short-term risk, COR is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check PBH's competition here
COR vs ACH Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, ACH has a market cap of 214.1M. Regarding current trading prices, COR is priced at $266.17, while ACH trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas ACH's P/E ratio is -2.04. In terms of profitability, COR's ROE is +1.16%, compared to ACH's ROE of +2.65%. Regarding short-term risk, COR is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check ACH's competition here
COR vs OMI Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, COR is priced at $266.17, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas OMI's P/E ratio is -0.47. In terms of profitability, COR's ROE is +1.16%, compared to OMI's ROE of +2.69%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check OMI's competition here
COR vs GEG Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, GEG has a market cap of 67.7M. Regarding current trading prices, COR is priced at $266.17, while GEG trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas GEG's P/E ratio is -2.70. In terms of profitability, COR's ROE is +1.16%, compared to GEG's ROE of -0.38%. Regarding short-term risk, COR is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check GEG's competition here
COR vs HX Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $266.17, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +1.16%, compared to HX's ROE of -1.07%. Regarding short-term risk, COR is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HX's competition here
COR vs WGRX Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, WGRX has a market cap of 11.7M. Regarding current trading prices, COR is priced at $266.17, while WGRX trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas WGRX's P/E ratio is -0.12. In terms of profitability, COR's ROE is +1.16%, compared to WGRX's ROE of +1417.60%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check WGRX's competition here
COR vs ZYXI Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, COR is priced at $266.17, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, COR's ROE is +1.16%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, COR is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ZYXI's competition here
COR vs SNYR Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, SNYR has a market cap of 2.6M. Regarding current trading prices, COR is priced at $266.17, while SNYR trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas SNYR's P/E ratio is -0.16. In terms of profitability, COR's ROE is +1.16%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, COR is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check SNYR's competition here
COR vs MEHA Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, MEHA has a market cap of 451.1K. Regarding current trading prices, COR is priced at $266.17, while MEHA trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas MEHA's P/E ratio is 6.55. In terms of profitability, COR's ROE is +1.16%, compared to MEHA's ROE of +11.59%. Regarding short-term risk, COR is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check MEHA's competition here
COR vs RDGT Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, RDGT has a market cap of 413. Regarding current trading prices, COR is priced at $266.17, while RDGT trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas RDGT's P/E ratio is -0.03. In terms of profitability, COR's ROE is +1.16%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check RDGT's competition here
COR vs CVET Comparison May 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 51.8B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $266.17, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 20.41, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +1.16%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CVET's competition here